Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, and sodium–glucose cotransporter 2 inhibitors (SGLT2is) both reduce chronic kidney disease (CKD) progression and improve kidney/cardiovascular (CV) outcomes. Here, NR3C2 is linked to chronic kidney disease.